The scale of the problem is striking. According to the World Obesity Atlas 2025, 22 percent of Bulgarian adults are living with obesity and 54 percent are classified as overweight, meaning around two-thirds of the adult population carries excess weight. Out of roughly 4.58 million adults above the age of 19, more than 2.47 million have a high body mass index and just over one million already meet the threshold for obesity. The researchers project that the number of adults with high BMI will climb to approximately 2.83 million by 2030, a trajectory that threatens to overwhelm a healthcare system already under strain.

To capture the full economic picture, the team conducted a quantitative cost-of-illness analysis from a societal perspective, using a top-down, population-based approach. They calculated direct medical costs, including anti-obesity medicines, hospitalisations, bariatric surgery, and the treatment of major complications such as type 2 diabetes, cardiovascular disease, and joint replacements requiring hip or knee surgery. Indirect costs were measured through productivity losses from absenteeism, and the social burden was quantified using disability-adjusted life years, or DALYs, a metric that combines years of life lost to premature death with years lived in less-than-full health.

The direct healthcare bill came to €55,935,208 for just the first six months of 2025. Two categories dominated: hospitalisations due to complications accounted for 47 percent of the total, while anti-obesity medicines made up 48 percent. The medicine figure rests on a deliberately optimistic assumption, since only 1.3 percent of patients eligible for obesity treatment actually fill at least one weight-loss prescription, based on published international data. Applying that rate to Bulgaria’s obese population yields roughly 13,096 people on pharmacotherapy, with the market split between liraglutide at 20 percent, semaglutide at 40 percent, and tirzepatide at 40 percent. Even at those modest uptake levels, six months of therapy across all eligible patients would cost about €26.6 million, with tirzepatide alone accounting for nearly €2.5 million per month.

Hospital care tells its own story. The researchers tallied costs across clinical pathways coded by the National Health Insurance Fund, finding that knee and hip replacements represented the single largest obesity-linked expenditure, at over €11.8 million for the half-year, reflecting evidence that more than half of joint replacement patients live with obesity. Decompensated type 2 diabetes hospitalisations added nearly €3.9 million, ischaemic stroke admissions without thrombolysis cost close to €6 million, and acute myocardial infarction contributed over €1.5 million. Reimbursed ambulatory medicines for complications, spanning dyslipidaemia, hypertension, and diabetes drugs, added another €2.4 million. Bariatric surgery, by contrast, remains rare: only 85 procedures were claimed in the half-year at an average price of about €4,750, totalling just over €400,000.

Perhaps the most consequential finding is that indirect costs exceed direct medical spending. Productivity losses from absenteeism, calculated from sick leave certificates issued between January and June 2025 and valued at the 2025 minimum daily wage of €26.22, reached €57,922,356 in six months. Workers aged 41 to 60 drove the largest share of these losses, and the researchers note a clear upward trend in sick leave days that may reflect the progressive nature of obesity and its comorbidities. Because the analysis captured only absenteeism and not presenteeism, the true productivity gap is almost certainly wider, meaning the imbalance between indirect and direct costs is even more pronounced than the headline figures suggest.

The social burden, expressed in DALYs, totalled 42,468 years for one year across five major obesity-related complications: diabetes mellitus, ischaemic heart disease, hypertensive heart disease, chronic kidney disease, and stroke. The methodology combined national mortality data from the Bulgarian National Statistical Institute and the World Health Organization with population attributable fractions, which estimate what share of each disease would not occur if obesity were absent, based on obesity prevalence and disease-specific relative risks drawn from the published literature. Years of life lost to premature death emerged as the larger contributor to the DALY total, with diabetes, ischaemic heart disease, and stroke standing out as the leading drivers of obesity-attributable disease burden in the country.

The authors are careful about the limits of their estimates. Direct healthcare costs are likely underestimated because anti-obesity medicines and most bariatric procedures are not reimbursed by public funds in Bulgaria, meaning patients pay out of pocket and the true economic flow is difficult to track; there is no national register of bariatric operations. The study also excluded more than 200 known obesity-related comorbidities, including cancer, metabolic dysfunction-associated steatotic liver disease, and sleep apnoea, so the actual cost of treating complications is higher still. Hospitalisation calculations assumed conservatively that each patient experienced only one complication per year. Private payments, adolescent obesity, and broader social consequences such as unemployment and reduced socioeconomic productivity were likewise outside the scope of the analysis.

What emerges is a picture consistent with global trends. Worldwide, 2.5 billion adults were overweight in 2021 and 890 million were living with obesity, and adult obesity has more than doubled since 1990. Excess body weight was linked to an estimated 3.7 million deaths from non-communicable diseases in 2021, and DALYs attributable to high BMI rose by 15.7 percent between 2000 and 2021, while metabolic risks overall increased by nearly 50 percent. In Bulgaria specifically, high body mass index contributed to an estimated 5,594 premature deaths and 90,695 adult person-years of ill health in 2021, and it now ranks as the fourth-leading risk factor for DALYs per 100,000 people, behind high blood pressure, dietary risks, and tobacco.

The study’s authors argue that the policy response has not kept pace with the science. Although new and effective anti-obesity pharmacotherapies have reached the market, their high prices and lack of public reimbursement, in Bulgaria and across most of Europe, keep them out of reach for most patients. Bulgarian clinical guidelines, last updated in 2017 and 2019, still recommend only older options such as orlistat, liraglutide, and naltrexone, and the researchers point to the United Kingdom’s National Institute for Health and Care Excellence as a model for evidence-based reimbursement criteria. They propose an action plan targeting high-risk groups, defined as individuals with a BMI above 35 kg/m² and at least one obesity-related condition, with anti-obesity treatment of fixed two-year duration. Given that obesity is a complex, progressive, relapsing chronic disorder requiring long-term management, the researchers conclude that acting now, before the projected 2030 surge in prevalence, could spare both the healthcare system and society a substantially larger bill.

Subject of Research: The economic and social burden of obesity in Bulgaria, quantified through a cost-of-illness analysis of direct healthcare costs, productivity losses, and disability-adjusted life years

Article Title: The economic and social burden of obesity in Bulgaria

Article References: Mihaylova, S., & Petrova, G. (2026). The economic and social burden of obesity in Bulgaria. Pharmacia, 73, Article e204540. https://doi.org/10.3897/pharmacia.73.e204540

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e204540

Keywords: obesity, Bulgaria, cost of illness, DALYs, health economics, anti-obesity medicines, absenteeism, type 2 diabetes, cardiovascular disease, bariatric surgery, public health, productivity losses

The headline numbers tell a story of genuine progress. In 1990, roughly 30,700 women of reproductive age were diagnosed with TBL cancer globally; by 2021 that figure had risen to about 45,900. Yet when adjusted for the age structure of the population, the incidence rate actually fell, from 2.73 cases per 100,000 women to 2.23 per 100,000—an estimated annual percentage change of −0.81 percent. Mortality tells a similar tale. Deaths rose in absolute terms, from about 26,100 to nearly 34,900 over the three decades, but the age-standardised death rate dropped from 2.32 to 1.70 per 100,000, an annual decline of 1.21 percent. The DALY rate, which combines years of life lost with years lived in disability, fell from 111.8 to 81.8 per 100,000 over the same period.

What makes these trends particularly striking is their shape. Rather than declining steadily, all three indicators followed a rise-then-fall trajectory. Incidence peaked in 2001, mortality in 2000 and DALYs in 1996, with the steepest declines occurring between 2010 and 2016. The researchers attribute this pattern to the long lag between smoking exposure and cancer development. Male smoking rates began falling immediately after the Second World War, while female rates rose after the war and only started to decline in the late 1960s. That delay pushed the peak of the lung cancer epidemic in women well behind that of men, and the timing of the observed peak in reproductive-age women fits this historical fingerprint precisely.

Beneath the averages, the biology of lung cancer in women is markedly different from that in men, and the study’s authors argue this has been underappreciated. Women who smoke face roughly three times the lung cancer risk of men who smoke at equivalent exposure, with higher levels of DNA adducts in lung tissue and a greater propensity for p53 and K-RAS mutations. The mechanism involves estrogen: the hormone can synergise directly with tobacco carcinogens such as benzo[a]pyrene, and estrogen receptor alpha upregulates the expression of CYP1A1 and CYP1B1, enzymes that metabolically activate polycyclic aromatic hydrocarbons in cigarette smoke. CYP1A1 expression in the lungs of female smokers can be nearly four times higher than in male smokers. Compounding this, women have comparatively weaker DNA repair capacity, allowing mutations to accumulate more readily.

Smoking, however, is only part of the picture for this population. Globally, about one-third of households still rely on biomass or coal for cooking, heating and lighting, and women of reproductive age bear the brunt of that exposure because they are typically responsible for preparing meals. In China, where fewer than 5 percent of women smoke, as many as 81.65 percent of female lung cancer cases are attributed to risk factors other than tobacco, with outdoor air pollution and indoor burning of solid fuels considered major contributors. A systematic review and meta-analysis cited in the study found that the lung cancer risk associated with solid fuel use is significantly higher among women, with an odds ratio of 1.81 compared with 1.16 for men. Exposure assessments in India have shown that women aged 15 to 40 who cook with solid fuels register the highest 24-hour average exposure concentrations of any household group.

The geographic distribution of the burden is profoundly uneven. Among the 21 GBD regions, East Asia recorded the highest incidence and mortality rates in 2021, at 4.75 and 3.39 cases per 100,000 respectively, a situation the researchers link to rapid economic development, lifestyle changes, high secondhand smoke exposure despite low female smoking rates, and indoor air pollution from cooking fumes and solid fuels. At the country level, Greenland had the highest incidence rate at 7.94 per 100,000, while Monaco recorded the highest mortality rate at 7.65 per 100,000. Nigeria had the lowest rates for both measures. China, by virtue of its enormous population, led the world in absolute case numbers, deaths and DALYs in both 1990 and 2021.

Stratifying the data by the Socio-Demographic Index—a composite measure of income, education and fertility—exposes a stark divergence. Only in low-SDI and lower-middle-SDI regions did incidence and mortality rates continue to rise between 1990 and 2021, while high-SDI regions saw accelerating declines from around 2010 onward. South Asia recorded the fastest-growing rates across all indicators, with an incidence EAPC of 1.53 percent, whereas high-income North America showed the steepest declines, at −2.83 percent for incidence and −3.22 percent for mortality. The researchers describe lower-middle-SDI regions as being in an

Subject of Research: Global burden and trends of trachea, bronchus and lung cancer in women of reproductive age from 1990 to 2021 with projections to 2035

Article Title: Trachea, bronchus, and lung cancer in women of reproductive age: global burden trends from 1990 to 2021 and forecasts to 2035

Article References: Chen, S., Rao, Y., Chen, Y., Yang, Q., Wu, G., Hu, F., Gao, Y., Pu, H., & Fu, J. (2026). Trachea, bronchus, and lung cancer in women of reproductive age: global burden trends from 1990 to 2021 and forecasts to 2035. Frontiers in Global Women's Health, 7, Article 1695260. https://doi.org/10.3389/fgwh.2026.1695260

Image Credits: AI Generated

DOI: 10.3389/fgwh.2026.1695260

Keywords: lung cancer, women's health, Global Burden of Disease, reproductive age, health inequality, tobacco control, air pollution, DALYs, Bayesian modelling, socio-demographic index, epidemiology, cancer projections

The numbers behind the study are stark. Between 2000 and 2023, tuberculosis DALYs—a composite measure combining years of life lost to premature death with years lived in disability—fell from 80.1 million to 43.6 million, a 45.6 percent drop. Adjusted for population growth, the rate fell even faster, from 1,306.6 to 542.9 per 100,000 people, a decline of 58.5 percent. Yet the residual burden is enormous and unevenly shared. The African Region recorded the highest rate in 2023 at 1,372.2 per 100,000, and because its decline lagged behind other regions, it overtook South-East Asia as the largest absolute contributor, with 17.0 million DALYs against 14.5 million—a reversal of the pattern seen in 2000. Low-income countries carried rates of 1,448.3 per 100,000, roughly forty times the 36.5 per 100,000 seen in high-income nations.

Progress has also been strikingly uneven across the human lifespan. Among children under fifteen, DALYs fell 56.9 percent over the study period, from 15.0 to 6.5 million. Working-age adults saw an intermediate decline of 45.1 percent. But among adults aged 65 and older—the group with the highest DALY rate in 2023 at 939.4 per 100,000—the drop was only 32.9 percent, from 11.2 to 7.5 million. As a result, older adults now account for 17.2 percent of the global tuberculosis burden, up from 14.0 percent in 2000. The authors attribute this pattern to cumulative lifetime exposure, immunosenescence, and age-related comorbidity, and they warn that programmatic gains achieved for children have simply not been matched among the elderly, who represent a growing share of the disease’s remaining toll.

Methodologically, the study is notable for the care with which it separates two very different questions. Using a within-between specification first formalized by economist Yair Mundlak in 1978, the researchers split each time-varying predictor into two components: a country’s long-term average level, and how far a given year’s value departs from that average. The first component answers whether countries that are usually more exposed also carry more tuberculosis burden; the second asks whether burden moves when a country temporarily rises above or falls below its own norm. This distinction matters because the two answers can diverge dramatically, and conflating them has muddied much of the earlier literature on the social and environmental determinants of tuberculosis.

The between-country results paint a coherent picture of entrenched burden. Comparing countries at the 75th versus the 25th percentile of each predictor’s long-term national distribution, DALY rates were 52.1 percent higher where the fraction of tuberculosis associated with HIV was higher, 38.1 percent higher where undernutrition was more prevalent, and a striking 88.4 percent higher where vulnerable employment—insecure, unprotected work—was more common. Conversely, rates were 58.3 percent lower in countries with stronger universal health coverage and 31.5 percent lower where tuberculosis treatment coverage was more complete. These are associations, not causal estimates, but they describe with unusual precision the national profile in which tuberculosis remains endemic: HIV-driven epidemic pressure, malnutrition, precarious labor, and thin health systems.

The within-country story is more sobering. Short-term changes in treatment coverage, treatment success, universal health coverage, undernutrition, vulnerable employment, and PM2.5 were not independently associated with subsequent changes in DALY rates in the primary model. The authors caution that this is not evidence the conditions are unimportant. Year-to-year program audits, they argue, are unlikely to detect the true impact of structural conditions on tuberculosis, because policy responses, shifts in case detection, biological lags, and epidemic history all blur short-term national trends. The practical implication is that the factors identifying a high-burden country are not automatically the same factors that produce an immediate, measurable decline when they change within that country—a lesson with real consequences for how global agencies design and evaluate interventions.

Where the study breaks new ground is in its temporal analysis of which national changes tracked faster or slower improvement. Of eight annualized predictors examined, only two survived false-discovery-rate correction: treatment success and ambient PM2.5. Improving treatment success was associated with a more favorable annualized DALY-rate trajectory, while rising PM2.5 tracked a less favorable trajectory of comparable magnitude in the opposite direction. Crucially, the PM2.5 signal persisted even after the researchers added annualized changes in GDP per capita and urban population share to the model, indicating that air pollution is not simply proxying for broader economic development. The biological plausibility is well established: particulate exposure damages airway and alveolar epithelium, impairs the phagocytic and bactericidal function of alveolar macrophages, and blunts the cell-mediated immune response required to contain Mycobacterium tuberculosis. Laboratory work has shown that urban airborne particles directly impair human lung and blood immunity to the bacillus.

The authors are careful about what this means. As an ecological analysis, the study cannot establish causality, and they flag important residual confounders, including smoking prevalence, occupational particulate exposure, crowding, and—perhaps most importantly—household air pollution from solid-fuel cooking and heating, which is a well-established tuberculosis risk factor in its own right, typically far more concentrated than ambient PM2.5, and inseparable from outdoor pollution in country-level data. They also note that no study has yet evaluated whether an actual air-quality policy intervention was followed by a measurable reduction in tuberculosis burden, a gap they identify as a research priority. Still, if the association is even partly causal, clean-air policies pursued for cardiovascular, respiratory, and climate reasons could carry an additional, currently uncounted tuberculosis benefit, particularly in the high-burden, high-pollution settings of South and Southeast Asia and sub-Saharan Africa.

The projections to mid-century give the findings a policy horizon. Fitting log-linear trends for each of twenty age groups in every country, partially pooling slopes toward regional medians, and running two thousand simulations that sampled slope uncertainty and correlated global and regional shocks, the researchers project median DALYs of 38.2 million in 2030, 32.9 million in 2040, and 29.4 million in 2050—only 32.5 percent below the 2023 level. Internal validation lent credibility to the short-term calibration: data through 2015 projected 2020 within 8.7 percent, and data through 2020 projected 2023 within 0.3 percent. Twenty-one countries are projected to have more tuberculosis DALYs in 2050 than in 2023, with India remaining the largest contributor, followed by the Democratic Republic of the Congo, Indonesia, Pakistan, and Nigeria. These figures are continuation scenarios, not inevitabilities; modeling studies show that vaccination, screening, preventive therapy, rapid diagnosis, and effective treatment could bend the curve far more sharply.

The study’s conclusion is ultimately a call to reframe the fight against tuberculosis. The global decline is real, but too slow to meet the End TB targets of an 80 percent reduction in incidence and a 90 percent reduction in deaths by 2030 relative to 2015. What emerges is a two-part agenda: sustained investment in treatment completion and universal health coverage, alongside coordinated action on the structural conditions—nutrition, social protection, HIV-related epidemic pressure, and now air quality—that determine where the disease takes root and how fast it recedes. The finding that national air-quality trajectories move in lockstep with national tuberculosis trajectories places TB control squarely within the climate-and-health agenda, and suggests that the lungs of the world’s poorest billions may depend as much on what is in the air as on what is in the medicine cabinet.

Subject of Research: Country-level longitudinal analysis of air pollution, health coverage, and structural determinants of global tuberculosis burden with projections to 2050

Article Title: Air Pollution, Health Coverage, and Global Tuberculosis Trajectories: A Longitudinal Country-Level Analysis with Projections to 2050

Article References: Buendía, J. A., & Martínez-Herrera, E. (2026). Air Pollution, Health Coverage, and Global Tuberculosis Trajectories: A Longitudinal Country-Level Analysis with Projections to 2050. Environmental Advances, Article 100768. https://doi.org/10.1016/j.envadv.2026.100768

Image Credits: AI Generated

DOI: 10.1016/j.envadv.2026.100768

Keywords: tuberculosis, air pollution, PM2.5, DALYs, universal health coverage, undernutrition, HIV, treatment success, Global Burden of Disease, projection to 2050, vulnerable employment, End TB Strategy

The Commission, co-chaired by Professor Christopher JL Murray, Director of the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, and Dr. Natalia Kanem, former Executive Director of the United Nations Population Fund, drew on the expertise of 35 leaders from health, economics, security, governance and technology. The authors examined hundreds of possible threats, using historical evidence and new risk analysis covering 204 countries and territories from IHME. From that long list, they identified seventeen threats that pose the greatest danger to human health and survival between 2025 and 2100, and for which governments, funders and industry have a realistic route to act through policy change, funding decisions and innovation.

The methodology behind the selection is deliberately rigorous. A threat was classified as catastrophic if it met three key criteria: it could account for at least one billion disability-adjusted life years, or DALYs, by 2100; there is sufficient data available to model the threat; and there is sufficient scope for policy action. DALYs measure the number of years in good health lost to sickness, disability or premature mortality that could be avoided with targeted action. For each of the seventeen threats, the Commission modelled a plausible best-case and worst-case future, and the gap between them, measured in amenable DALYs, shows decision-makers exactly where investment and innovation can make the greatest difference.

Two of the seventeen threats stand apart because of their extinction potential: the malicious use of artificial intelligence and nuclear conflict. While the likelihood of either remains comparatively low, their consequences are so severe that the Commission treats them as consequential threats demanding urgent preventive action. Accounting for both potential impact and probability, the assessment finds that action to prevent nuclear conflict could avert an estimated 133 million deaths and 9.35 billion DALYs by 2100, while action to reduce the risk of malicious AI could avert an estimated 10.4 billion DALYs. These figures underline the Commission’s central argument that low-probability, high-consequence events cannot be excluded from rational long-term health planning.

The remaining fifteen catastrophic threats read like a catalogue of the century’s most pressing challenges: air pollution, antimicrobial resistance, childhood malnutrition, climate change, conventional conflict, declining development assistance for health, high alcohol use, high blood pressure, income inequality, low educational attainment, naturally occurring pandemics, obesity, poor mental health, smoking and unhealthy ageing. Several of these are already imposing substantial health burdens today, while others carry a real danger if they materialize. Crucially, the Commission emphasizes that all seventeen threats are interconnected, which is why the authors insist they must be addressed together rather than in isolation. Climate change, for example, intensifies other risks such as migration pressures in ways not yet reflected in the current numbers.

Some of the quantified findings are striking. Climate change is described as already a catastrophic and urgent threat to health and human survival. The Commission finds that limiting global warming to around 1.8 degrees Celsius, rather than letting it reach 4.4 degrees, could prevent 1.89 billion years of healthy life from being lost to causes like extreme heat and air pollution. The true burden is likely even greater, because this estimate captures only direct harms that can be measured today, excluding harder-to-quantify effects such as displacement, drought and mental health impacts. Without sharp cuts to emissions, these losses will continue to compound beyond 2100.

Socioeconomic factors emerge as enormous levers of health. The Commission calculates that 16.1 billion DALYs are amenable to improvements in educational attainment, with women and children in sub-Saharan Africa facing the greatest potential burden of associated health loss. Faster progress on education would substantially improve health outcomes and reduce mortality rates among the children of educated mothers, while indirectly contributing to slower population growth over the longer term. Income inequality, meanwhile, could impose an amenable health burden equivalent to twenty-five COVID-19 pandemics by 2100, accounting for an estimated 13.8 billion DALYs. Obesity is forecast to compound over time, contributing 23.1 billion potential DALYs by 2100 that could be avoided through policies to reduce obesity risk. Sub-Saharan Africa is forecast to bear around seventy percent of the amenable health burden linked to a collapse in development assistance for health.

If current trends continue, the seventeen catastrophic threats collectively could account for tens of billions of years of lost health. While the scale varies by threat and region, every country faces significant risks, and within each country the harms will be distributed unequally, with people in resource-limited settings and marginalized communities bearing the greatest burden, compounded by existing inequalities. Professor Murray notes that the striking finding is not only the scale of these threats but that humanity still has the agency to act, warning that delaying action will only serve to shift and increase the costs into the future. Dr. Kanem adds that recent global events show how quickly stability can give way to crisis, and how costly it is to respond only after disaster strikes, yet the future is not inevitable.

To convert analysis into action, the Commission proposes a three-part agenda: build, back and track. Building readiness means creating and funding threat-ready health systems with dedicated teams for foresight, prevention, preparedness and protection across a wide range of risks, embedded in how health systems are funded and delivered, supported by durable financing rather than ad hoc crisis responses, and designed to reach lower-resource settings and marginalized communities. Backing breakthroughs means increasing investment in innovation where existing tools are insufficient, including new vaccines, antibiotics, obesity treatments and climate technologies, alongside appropriate governance and equitable access. Tracking threats means regular and independent reassessment so that evidence keeps pace with emerging risks and reaches decision-makers in finance and security as well as health, including the creation of a Lancet Monitor of 21st Century Global Threats to Health as an institutionalized tracking mechanism.

The Commission does not present a fixed ranking of threats or policy priorities. As an accompanying Lancet Editorial makes clear, the report’s analysis should be seen as a dynamic process whose findings will probably change as new evidence and data are accrued. Lancet Editor-in-Chief Dr. Richard Horton describes the work as a radical conceptual shift in how humanity thinks about future threats to survival, inviting a move from single issues to a broader and more complex landscape of dangers that demands a much more extensive framework for coordinated action. The report’s authors hope the framework will catalyze international, regional and national action, helping leaders identify opportunities for collaborative, cross-sectoral responses that build societies resilient to global threats, protect economies and security, and secure a fairer and more peaceful future for coming generations.

Subject of Research: Global catastrophic threats to human health and survival, including climate change, nuclear conflict, malicious AI and socioeconomic risks, and policy strategies to mitigate them by 2100

Article Title: The Lancet: New Commission provides roadmap to protect economies, security and global stability from catastrophic threats to health and human survival

Article References: The Lancet: New Commission provides roadmap to protect economies, security and global stability from catastrophic threats to health and human survival. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: The Lancet, global health, catastrophic threats, DALYs, climate change, nuclear conflict, artificial intelligence, IHME, health policy, pandemics, income inequality, obesity

The condition itself is deceptively common. Roughly 60 percent of term newborns and 80 percent of preterm infants develop some degree of jaundice, the yellowing of skin and eyes that occurs when bilirubin, a breakdown product of hemoglobin, accumulates faster than the immature liver can clear it. In most cases the pigment fades without consequence. But when bilirubin levels climb to extreme concentrations, the molecule crosses the blood-brain barrier and binds to brain tissue, producing acute bilirubin encephalopathy and, in its chronic form, kernicterus, a devastating and permanent neurological injury marked by hearing loss, movement disorders, and intellectual disability. The tragedy, as the new analysis makes painfully clear, is that virtually every one of these deaths and injuries is preventable with timely screening, accurate bilirubin measurement, and phototherapy, a treatment that costs pennies per hour to deliver.

To map the trajectory of the disease, the author of the study drew on the Global Burden of Disease 2023 dataset, which models disease incidence, mortality, and disability-adjusted life-years, or DALYs, across 204 countries and territories. The analysis focused on extreme hyperbilirubinemia, the severe end of the spectrum responsible for death and disability, and tracked three decades of change from 2003 through 2023. Rather than relying on simple before-and-after comparisons, the study employed joinpoint regression, a statistical technique borrowed from cancer surveillance that identifies the years in which trends genuinely shifted direction, allowing the researcher to detect whether progress accelerated or stalled at particular moments. The work also applied k-means clustering to group countries by burden patterns within World Bank income strata, and used correlation analysis to probe the relationship between how often babies fall ill and how often they die.

The headline numbers are striking. Global incident cases of extreme hyperbilirubinemia fell from 542,966 in 2003 to 387,366 in 2023, a 29 percent decline. Deaths plummeted even faster, from 70,907 to 24,050, a 66 percent reduction. The mortality-to-incidence ratio, a rough proxy for how lethal the condition is once a baby is affected, halved from 13.1 percent to 6.2 percent over the two decades. Joinpoint regression quantified the pace of change: incidence declined at an average annual rate of 1.5 percent, while mortality fell at 5.0 percent per year. The fact that mortality fell more than four times faster than incidence suggests that something changed not merely in how many babies develop dangerous jaundice, but in how health systems respond when they do.

That something, the analysis implies, is the gradual diffusion of the basic toolkit of newborn jaundice care: risk assessment before discharge, transcutaneous and serum bilirubin measurement, exchange transfusion capacity, and above all phototherapy, the blue-light treatment that converts bilirubin into water-soluble forms the infant body can excrete. In wealthy countries, extreme hyperbilirubinemia has become vanishingly rare, and national guidelines from bodies such as the American Academy of Pediatrics have been repeatedly refined to standardize screening thresholds and treatment escalation. In Sweden, for example, population-based studies have documented rates of kernicterus so low that individual cases trigger national investigations into guideline adherence. The new global analysis shows that the benefits of this standard of care are no longer confined to high-income settings, even though they have not yet reached them equally.

The geography of the remaining burden is starkly concentrated. In 2023, South Asia and Sub-Saharan Africa together accounted for 68 percent of the world’s incident cases and a staggering 90 percent of deaths. Three countries, India, Pakistan, and Nigeria, alone represented roughly half of global mortality from the condition. Lower-middle-income countries bore about two-thirds of all deaths and DALYs. The Middle East and North Africa region recorded the most dramatic improvements, cutting cases by 61 percent and deaths by 72 percent over the study period, a pace of progress that demonstrates how rapidly the burden can fall when health systems invest in newborn care at scale.

One of the most revealing findings of the study lies in its correlation analysis. In low-income countries, the incidence of extreme hyperbilirubinemia and its mortality remained tightly coupled, with a correlation coefficient of 0.72, meaning that wherever more babies fell severely ill, more babies died. In upper-middle-income countries, by contrast, the two measures had decoupled almost entirely, with a correlation of just 0.19 that was no longer statistically significant. This decoupling is a signature of functioning health systems: it indicates that even when babies develop dangerous jaundice, effective screening and treatment intervene before the disease turns fatal. In the poorest settings, the tight coupling reveals the opposite reality, that access to care, not the underlying biology of the disease, determines whether a jaundiced newborn survives.

The study also translated the human toll into economic terms, using two complementary valuation frameworks. Applying the value-per-statistical-life approach, which estimates welfare losses based on how much societies are willing to pay to reduce mortality risk, the 2023 burden represented between 6.9 and 10.4 billion dollars in losses. A second calculation based on DALYs and the human-capital method, which values lost productive years of life, yielded an estimated 13.0 billion dollars in annual losses. These figures, the analysis argues, provide policymakers with a benchmark against which the cost of scaling up screening programs, phototherapy units, and referral networks can be judged, and the arithmetic favors investment decisively, since the interventions required are among the cheapest in all of medicine.

The methodological choices matter for interpreting these results. The Global Burden of Disease project synthesizes vital registration data, surveillance systems, and statistical modeling, which means estimates for countries with weak civil registration systems carry substantial uncertainty, and the true burden in the hardest-hit regions may be undercounted rather than overstated. The k-means clustering within World Bank income groups revealed that countries at similar income levels followed divergent burden trajectories, hinting that political commitment and health-system design, not just national wealth, shape outcomes. The author notes that the analysis, conducted with publicly available anonymized data, was exempt from institutional review board review, and reports no competing interests.

What emerges from two decades of data is a story of remarkable but unfinished progress. A condition that once killed one in eight babies who developed its extreme form now kills one in sixteen globally, and in the best-performing health systems it kills almost no one. Yet 24,050 newborn deaths in a single year, nearly all concentrated in a handful of countries and almost all preventable with tools that cost little more than a lightbulb and a trained eye, represent a measure of how far the global newborn health agenda still has to travel. The study points to the next frontier: linking burden estimates to concrete measures of screening coverage, bilirubin testing quality, phototherapy availability, and referral capacity, so that the decoupling of illness from death achieved in middle-income countries can be replicated where it matters most, in the delivery rooms of South Asia and Sub-Saharan Africa.

Subject of Research: Global trends and economic burden of neonatal hyperbilirubinemia from 2003 to 2023

Article Title: Global, regional, national trends and economic evaluation of neonatal hyperbilirubinemia burden, 2003–2023

Article References: Vidavalur, R. (2026). Global, regional, national trends and economic evaluation of neonatal hyperbilirubinemia burden, 2003–2023. Pediatric Research. https://doi.org/10.1038/s41390-026-05541-z

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05541-z

Keywords: neonatal hyperbilirubinemia, kernicterus, Global Burden of Disease, phototherapy, neonatal mortality, DALYs, health economics, South Asia, Sub-Saharan Africa, joinpoint regression, newborn jaundice, health disparities

The scale of the underlying problem is enormous. Rare diseases are individually defined as affecting fewer than 1 in 2,000 people, but more than 7,000 distinct types are currently recognized, and recent estimates suggest the true number may exceed 10,000. Collectively, rare diseases affect roughly 3.5 to 5.9 percent of the global population, equivalent to between 263 and 446 million individuals. Nearly half of all rare diseases are neurological in nature, and around 90 percent of rare childhood diseases involve major neurological manifestations. Approximately 80 percent of rare diseases are genetic in origin, nearly 70 percent of those present during childhood, and about 30 percent of affected children die before their fifth birthday. These figures underscore why rare neurological diseases in children represent a disproportionate share of the global rare disease burden.

To isolate this population, the research team applied three criteria to the GBD 2021 cause hierarchy: relevance to children aged 0 to 14, a prevalence threshold of no more than 50 per 100,000 people, and availability as a distinct disease category permitting population-level estimation. Four groups emerged: motor neuron disease, multiple sclerosis, neuroblastoma and other peripheral nervous cell tumors (NPNCT), and a residual category of other neurological disorders that largely comprises inherited neuromuscular conditions such as muscular dystrophies and myopathies. The team computed age-standardized prevalence, mortality, and disability-adjusted life-year (DALY) rates, stratified by age, sex, and sociodemographic index (SDI), and quantified temporal trends using the average annual percentage change (AAPC).

The headline numbers tell a story of expanding prevalence. Globally, the number of prevalent cases rose by 21.98 percent, from roughly 80,785 in 1990 to 98,541 in 2021. The age-standardized prevalence rate climbed 7.17 percent, from 4.60 to 4.93 per 100,000 population, with an AAPC of 0.21 percent. DALYs increased even faster, rising 30.46 percent from 1.01 million to 1.32 million, with the age-standardized DALY rate up 14.92 percent. In contrast, the age-standardized mortality rate fell 6.98 percent, from 0.43 to 0.40 per 100,000. Children under five carried the heaviest burden in 2021, with the highest prevalence, DALY, and mortality rates of any age group, and prevalence rates rose across all pediatric age groups over the study period.

The four disease groups followed strikingly divergent trajectories. NPNCT had the highest prevalence rate in 2021 at 2.62 per 100,000 and the steepest increase, with an AAPC of 0.54 percent, and it was the only condition whose mortality rate rose. Other neurological disorders, dominated by monogenic neuromuscular diseases, were the leading contributor to disability alongside NPNCT, with a DALY rate AAPC of 0.73 percent. Multiple sclerosis showed a statistically significant but epidemiologically modest rise in prevalence. Motor neuron disease, by contrast, declined across all three measures, with its prevalence rate falling 6.37 percent. The authors attribute this decline partly to advances in prenatal diagnosis, newborn screening, and disease-modifying therapies for conditions such as spinal muscular atrophy, though they caution that uncertainty in GBD estimates for rare pediatric motor neuron diseases is considerable.

Boys consistently bore a higher burden than girls across prevalence, DALYs, and mortality, and the gap widened over time, with boys’ prevalence rate rising faster than girls’. The sex disparity echoes broader GBD 2021 findings across 37 neurological conditions, but this analysis confirms it emerges early in childhood. The authors note that the difference may partly reflect biological factors but also unequal healthcare access and diagnostic ascertainment between boys and girls, particularly in low-SDI countries, and they urge caution in interpretation.

The geographic patterns are perhaps the most consequential finding. High-SDI countries recorded the highest overall rates in 2021, at 9.33 per 100,000 for prevalence, yet all their rates have declined steadily since 1990, plausibly reflecting improvements in early diagnosis, multidisciplinary care, and supportive treatment. The opposite occurred in lower-development settings: middle-, low-middle-, and low-SDI countries all experienced rising prevalence, disability, and mortality, with the pace of increase inversely related to SDI. Low-middle-SDI countries saw the fastest prevalence growth, with an AAPC of 0.87 percent. Across countries, SDI values correlated strongly with prevalence rates, at r = 0.91. South Asia recorded the sharpest regional rise in prevalence, while Western sub-Saharan Africa saw the largest increases in disability and mortality. At the national level, 116 of 204 countries and territories showed rising prevalence, with Guyana experiencing the steepest increase, and India, China, and Pakistan reporting the highest absolute case counts in 2021.

Decomposition analysis revealed what is driving these increases. Population growth accounted for 73.33 percent of the global rise in prevalent cases, with true change in prevalence contributing 35.28 percent. In low- and low-middle-SDI countries, demographic expansion was the dominant force, whereas in middle-SDI regions and several high-case countries, rising prevalence itself played the leading role. The authors interpret the rising recorded prevalence largely as a product of diagnostic progress: newborn screening, next-generation sequencing, and single-molecule sequencing have dramatically improved case ascertainment, with roughly 250 to 280 newly described rare disorders reported annually since 2010. Longer survival among affected children, enabled by expanding targeted therapies, further inflates measured prevalence and DALYs even as mortality falls.

Looking forward, the team built a customized forecasting framework combining Poisson regression on SDI with an autoregressive integrated moving average model applied to regression residuals, integrating four models through root-mean-squared-error-weighted averaging, with ridge regularization and a quadratic SDI term to improve stability. Validated against withheld 2011 to 2021 data, the model achieved a mean absolute percentage error of just 0.62 percent. Its projections indicate that by 2050, prevalent cases will reach approximately 110,200, an 11.83 percent increase from 2021, with the age-standardized prevalence rate climbing to 5.62 per 100,000. Children under five will see the fastest growth, and Western sub-Saharan Africa, Southern sub-Saharan Africa, and South Asia the sharpest regional rises, with 132 countries expected to show increasing prevalence trends. The authors acknowledge that future gene therapies and expanded genomic screening could alter these trajectories in ways the model cannot capture.

To complement the epidemiological picture, the researchers mined ClinVar for genetic evidence of rare monogenic neurological diseases, compiling a curated list of 520 disease-causing genes. Between 1990 and 2024, the database recorded 65,331 pathogenic or likely pathogenic variants in these genes. The acceleration is dramatic: only 1,633 variants were reported between 1990 and 2010, compared with 18,851 in the following decade and 44,847 in just 2021 to 2024, alongside 55 newly reported disease-causing genes in the most recent period alone. The largest genetic evidence base lies within the other neurological disorders category, dominated by inherited neuromuscular diseases, of which more than 600 monogenic forms have now been identified. The authors stress that these figures reflect testing availability and submission practices, which skew toward high-income countries, rather than the true underlying genetic burden. Even so, the convergence of rising prevalence, accelerating genetic discovery, and widening global inequality paints a clear picture: rare childhood neurological diseases are becoming a growing and increasingly tractable global health challenge, one that will demand strengthened surveillance, equitable diagnostic access, and sustained investment in the low- and middle-income countries where the burden is now rising fastest.

Subject of Research: Global epidemiological and genetic burden of rare neurological diseases in children

Article Title: Global epidemiological and genetic burden of rare neurological diseases in children

Article References: Xie, Z., Sun, C., Liang, W., Zhao, X., Miao, L., Liu, X., Lu, Y., Liu, C., Yin, Z., Li, J., & Xie, Z. (2026). Global epidemiological and genetic burden of rare neurological diseases in children. iScience, 29(11), Article 117791. https://doi.org/10.1016/j.isci.2026.117791

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117791

Keywords: rare diseases, neurology, pediatrics, Global Burden of Disease, genetics, ClinVar, neuromuscular diseases, neuroblastoma, health inequality, epidemiology, DALYs, disease forecasting

The headline numbers reveal a striking asymmetry between absolute scale and population-adjusted rates. In 2023, China recorded approximately 103,000 pancreatic cancer cases, substantially more than the 66,000 cases documented in the United States. Yet when the researchers adjusted for age structure, the picture inverted: China’s age-standardized prevalence stood at 4.51 per 100,000 people, compared with 11.19 in the United States, and its age-standardized mortality rate was 4.97 per 100,000 against 9.56 in the American population. This contrast reflects the interplay of population size, demographic aging, and underlying exposure to risk factors, and it underscores why raw case counts alone can mislead when comparing disease burden across countries with very different demographic profiles.

Trends over time added further nuance to the comparison. Between 1990 and 2023, the absolute burden of pancreatic cancer grew in both countries, a trajectory shaped by aging populations, population growth, and shifting exposures to known and suspected risk factors. However, when the researchers examined age-standardized DALYs, a metric that corrects for changes in population size and age composition, they found that China experienced a slight decline of 0.15 percent, while the United States saw a modest increase of 0.12 percent. Though these percentage changes appear small, they point in opposite directions and suggest that the two nations may be traveling along different epidemiological paths, with China potentially benefiting from earlier stages of its demographic and lifestyle transition and the United States confronting the cumulative consequences of metabolic disease.

Age distribution emerged as another point of divergence. In China, the burden of pancreatic cancer peaked among people aged 60 to 74, whereas in the United States the peak had shifted to an older bracket, ages 70 to 84. This difference in age patterning has practical consequences for health systems. It means that in China, pancreatic cancer strikes a working-age and recently retired population, amplifying the socioeconomic cost of each case through lost productivity and years of life lost, while in the United States the disease increasingly concentrates among the very old, placing demands on geriatric oncology services, palliative care infrastructure, and long-term support systems for elderly patients and their families.

Perhaps the most consequential finding of the study concerns the changing hierarchy of modifiable risk factors. In the United States, high fasting plasma glucose has overtaken tobacco use as the leading attributable risk factor for pancreatic cancer DALYs. In China, high fasting glucose has risen to become a major contributor, now roughly comparable to tobacco in its population-attributable impact. The researchers measured this using population attributable fractions, or PAFs, which quantify the proportion of disease burden that could theoretically be eliminated if a specific risk factor were removed at the population level. The ascent of metabolic risk factors in both countries signals a fundamental shift in the prevention landscape, one that moves pancreatic cancer control increasingly into the domain of diabetes management, obesity prevention, and metabolic health.

This shift is biologically plausible and fits within a broader scientific understanding of pancreatic carcinogenesis. Chronic hyperglycemia, insulin resistance, and type 2 diabetes have been repeatedly associated with elevated pancreatic cancer risk in epidemiological studies, and the pancreas is an organ exquisitely sensitive to metabolic stress. At the same time, the decline of tobacco as the dominant attributable factor in the United States reflects decades of successful smoking control, a public health achievement that has reduced smoking prevalence substantially since the 1960s. The Chinese trajectory differs: smoking remains widespread, particularly among men, so tobacco continues to exert a heavy toll even as metabolic risk factors rise rapidly alongside economic development, dietary change, and increasing rates of overweight and diabetes.

The study also examined the socioeconomic dimensions of pancreatic cancer burden, and here the findings were sobering. Globally, the burden of the disease remained concentrated in regions with a high socio-demographic index, a composite measure of income, education, and fertility that serves as a proxy for overall development. More troubling still, absolute socioeconomic inequality in pancreatic cancer burden increased over the study period. This pattern suggests that as some populations gain access to better diagnostics, registration, and care, the measured and actual burden accumulates disproportionately among wealthier and more developed settings, while gaps between the best-off and worst-off regions widen rather than narrow. For a disease that is already difficult to diagnose early and harder still to treat, such inequities compound the challenge of mounting an effective global response.

The methodological backbone of the analysis deserves attention, because it illustrates how modern burden-of-disease research works. The Global Burden of Disease Study synthesizes data from vital registration systems, cancer registries, and modeling approaches to produce comparable estimates across countries and years, complete with 95 percent uncertainty intervals that convey the precision of each figure. By combining these estimates with population attributable fractions for individual risk factors, the researchers could rank the drivers of pancreatic cancer DALYs in each country and track how those rankings changed between 1990 and 2023. This framework transforms raw epidemiological surveillance into actionable intelligence, allowing policymakers to see not just how much disease exists but which modifiable exposures contribute most to it and how those contributions are evolving.

The research was led by investigators including Dr. Yifei Hu of the School of Public Health at Capital Medical University in Beijing and Dr. Wenming Wu of the Department of General Surgery at Peking Union Medical College Hospital, and it was funded by the Beijing Natural Science Foundation and the National Natural Science Foundation of China. The authors conclude that tailored, country-specific prevention strategies will be essential to curb the growing burden of pancreatic cancer in the coming decades, with particular emphasis on addressing the rising tide of metabolic risk factors. For the United States, that means treating glycemic control and diabetes prevention as cancer prevention, while for China it demands a dual strategy that confronts both the entrenched tobacco epidemic and the accelerating metabolic transition simultaneously.

The broader lesson of this study extends beyond two countries. Pancreatic cancer is projected to remain a leading cause of cancer death worldwide, and its resistance to early detection and treatment makes prevention the most powerful available lever. As populations age and metabolic diseases proliferate across the globe, the findings from China and the United States offer a preview of what many nations may face: a rising tide of pancreatic cancer whose risk profile is shifting from behavioral exposures like smoking toward metabolic conditions like hyperglycemia. Health systems that anticipate this shift, investing in diabetes prevention, metabolic screening, and equitable access to care, may be better positioned to blunt the impact of one of medicine’s deadliest diseases before its burden becomes unmanageable.

Subject of Research: Comparative burden and risk factors of pancreatic cancer in China and the United States, 1990–2023

Article Title: Pancreatic cancer burden rises in both China and the US, but patterns diverge

Article References: Pancreatic cancer burden rises in both China and the US, but patterns diverge. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pancreatic cancer, Global Burden of Disease, DALYs, high fasting glucose, tobacco use, China, United States, population attributable fraction, metabolic risk factors, age-standardized mortality, socioeconomic inequality, cancer prevention

The headline finding is a paradox that defines modern cancer epidemiology across much of Asia. Total leukemia incidence rose by 50.67 percent over the study period, a figure driven largely by population growth and the aging of hundreds of millions of people into age brackets where blood cancers become more common. Yet when the researchers adjusted for those demographic shifts, using age-standardized rates that allow fair comparison across populations and eras, the burden measured in disability-adjusted life years, or DALYs, actually fell by 16.2 percent. DALYs combine years of life lost to premature death with years lived in disability, offering a composite measure of a disease’s true footprint. A declining age-standardized DALY rate alongside rising raw case counts tells a story of medical progress: more people are being diagnosed, but fewer are dying young or living with severe disability from leukemia than would have been expected three decades ago.

Perhaps the most striking subtype-specific revelation concerns chronic lymphocytic leukemia, or CLL, a slow-growing cancer of B lymphocytes that was once considered comparatively rare in Asian populations. The study found that CLL has emerged as the predominant leukemia subtype in the region, a shift that carries both biological and diagnostic implications. CLL incidence showed a positive correlation with the Socio-demographic Index, a composite measure of income, education, and fertility used by GBD researchers, with a correlation coefficient of 0.32 that reached statistical significance. In plain terms, the wealthier and more developed a country or region, the more CLL appears within its leukemia profile. Whether this reflects genuine differences in disease biology, greater longevity allowing indolent cancers to surface, or simply more sophisticated diagnostic infrastructure detecting cases that would previously have gone unrecognized remains an open question that the epidemiological data alone cannot fully resolve.

The methodological machinery behind these conclusions deserves attention, because it represents the current state of the art in population-level cancer surveillance. The researchers employed joinpoint regression, a statistical technique that identifies points in time where the direction or magnitude of a trend changes significantly, allowing them to detect inflection moments that a simple linear analysis would smooth over. They complemented this with Bayesian age-period-cohort models, a framework that disentangles three intertwined influences on disease rates: the effect of a person’s age, the effect of the calendar era in which they live, and the effect of the birth cohort they belong to, which captures exposures and conditions shared by generations. By fitting these models to historical data, the team generated projections to 2030 that come with quantified uncertainty, a discipline that separates serious forecasting from speculation.

Those projections reveal a divergence that maps almost perfectly onto economic development. The age-standardized incidence rate of CLL is forecast to increase by 1.31 percent in middle Socio-demographic Index regions by 2030, while simultaneously decreasing by 0.98 percent in high SDI regions. This crossover is more than a statistical curiosity. It suggests that countries undergoing rapid development may be entering a phase where lifestyle and environmental transitions, combined with expanding diagnostic capacity, push CLL rates upward, whereas the wealthiest nations, having passed through that transition, are beginning to see their rates plateau or decline. For health ministries across South and Southeast Asia, the implication is that the leukemia challenges of the coming decade will not resemble those of the past one, and planning based on outdated subtype distributions risks misallocating scarce resources.

The risk factor analysis grounds these abstract trends in concrete, modifiable behaviors, and it is here that the study’s regional heterogeneity becomes most vivid. In Lebanon, smoking accounted for 29.0 percent of CLL deaths, a proportion that underscores the established link between tobacco exposure and lymphoid malignancies and points directly to tobacco control as a leukemia prevention strategy. In Kuwait, high body mass index contributed to 24.2 percent of leukemia deaths, highlighting the growing recognition that obesity-related metabolic inflammation is not merely a cardiovascular and diabetes concern but a meaningful cancer risk factor as well. That two different countries, facing different dominant risk factors, show such divergent profiles within a single disease category illustrates why the authors argue so forcefully for region-specific prevention strategies rather than continent-wide prescriptions.

The five subtypes examined behave almost like separate diseases, which in biological terms they largely are. Acute myeloid leukemia, a rapidly progressive malignancy of the myeloid blood cell lineage, demands intensive chemotherapy and often stem cell transplantation, and its burden reflects the availability of sophisticated hematology services. Chronic myeloid leukemia, once a death sentence, was transformed by tyrosine kinase inhibitors in the early 2000s into a manageable chronic condition, and declining mortality trends across Asia partly reflect the diffusion of these targeted therapies. Acute lymphoblastic leukemia remains the most common childhood cancer worldwide, with cure rates in well-resourced pediatric oncology centers now exceeding ninety percent, though outcomes in lower-income settings lag far behind. Chronic lymphocytic leukemia, the study’s newly dominant subtype, often requires no immediate treatment at all, following instead a watch-and-wait approach for many patients. Each subtype therefore responds differently to health system investments, and aggregating them obscures exactly the information policymakers need.

The spatial patterns the study documents across 49 countries and territories, stratified by Socio-demographic Index quintiles, add another layer of nuance. Asia is not a uniform block: it contains some of the wealthiest societies on Earth alongside nations where hematology services remain rudimentary. The estimated annual percentage changes in death rates and DALY rates varied substantially across regions for each subtype, with uncertainty intervals that in some cases crossed zero, signaling genuine ambiguity about trend direction. This heterogeneity is itself a finding. It means that a physician in Tokyo, a public health official in Dhaka, and a researcher in Shanghai are effectively confronting different epidemiological landscapes under the same disease umbrella, and that continental averages, however useful for global comparison, conceal the local realities where care is actually delivered.

What makes this analysis resonate beyond hematology is what it reveals about the epidemiological transition now sweeping through low- and middle-income countries. As infectious disease mortality falls and life expectancy rises, cancer becomes the frontier, and leukemia, with its subtype-specific dependence on age structure, diagnostics, and treatment access, serves as a sensitive barometer of that transition. The Shanghai-based team, supported by the Program of Shanghai Academic Research Leader, has produced a dataset that other regions could emulate, and their central message is hard to overstate: the era of treating leukemia as a single public health problem is over. The rising tide of new diagnoses will continue as Asia’s population ages, but the falling tide of age-standardized death and disability shows that prevention, early detection, and targeted therapy are working where they reach people. The task for the next decade, the data suggest, is ensuring they reach everyone, from the smoking-cessation clinics of the Levant to the obesity-prevention programs of the Gulf to the diagnostic laboratories of the developing economies where CLL’s rise is only beginning.

Subject of Research: Epidemiological trends and spatial patterns of five leukemia subtypes across Asia from 1990 to 2021 based on Global Burden of Disease data

Article Title: Temporal trends and spatial patterns of leukemia subtypes in Asia, 1990–2021: a global burden of disease study

Article References: Jiang, N., Yao, R., Zhou, H., Yan, W., Liu, W., Dai, X., Jin, Z., Yu, G., Kang, M., & Yin, J. (2026). Temporal trends and spatial patterns of leukemia subtypes in Asia, 1990–2021: a global burden of disease study. Annals of Hematology. https://doi.org/10.1007/s00277-026-07232-5

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07232-5

Keywords: leukemia, chronic lymphocytic leukemia, Global Burden of Disease, Asia, cancer epidemiology, Socio-demographic Index, DALYs, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, risk factors, disease projection

The scale of exposure is striking. Researchers estimate that 241 million people aged 15 years and older were chewing tobacco users in 2023, a global prevalence of 3.9 percent, with use more than twice as common among males as among females. Despite decades of progress in tobacco control that has driven down smoking rates in many parts of the world, the global prevalence of chewing tobacco use has remained essentially unchanged. No country recorded a significant decrease in the number of users between 1990 and 2023, while 24 countries saw significant increases in the size of their chewing tobacco populations. That stagnation stands in sharp contrast to the trajectory of smoked tobacco and suggests that chewing products have largely escaped the taxation, advertising bans, and public awareness campaigns that have reshaped cigarette consumption.

Geographically, the burden maps onto a narrow band of the planet. South Asia had the highest regional concentration of use, with 14.6 percent of people aged 15 and older using chewing tobacco in 2023, and the region accounted for an estimated 210,000 chewing tobacco-related deaths, about 84 percent of the global total. At the country level, age-standardized prevalence reached 24.4 percent in Palau, followed by Bangladesh at 23.4 percent and Nepal at 17.5 percent. More than 90 percent of male chewing tobacco-related deaths and disability occurred in just ten countries: India, Bangladesh, China, Pakistan, Myanmar, the United States, Nepal, Sri Lanka, the Philippines, and Madagascar. Among females, more than 90 percent of the burden was concentrated in India, Bangladesh, Pakistan, Indonesia, Myanmar, China, Thailand, Cambodia, Vietnam, and Nepal. The researchers caution that these figures reflect absolute numbers of deaths and disability, so countries with larger populations can account for a greater share of the burden even when their per-capita rates are not the highest.

“Chewing tobacco is not a uniform public health problem, and our findings show that a relatively small number of countries bear an overwhelming share of its health burden,” said Gabriela Gil, lead author and Research Scientist at IHME. “Understanding how patterns of use differ within these populations is critical to designing more effective prevention and tobacco control strategies.” Her point underscores a methodological strength of the new analysis: by disaggregating chewing tobacco from other smokeless products and estimating exposure country by country, the study gives policymakers a far more granular picture of where interventions are likely to yield the greatest returns.

The demographic architecture of chewing tobacco use differs sharply by age and sex, and those differences vary by setting in ways that complicate prevention. Globally, use was more common among males, rising through early adulthood and continuing to climb with age before peaking among people aged 60 to 64. In South Asia, nearly one in five males and one in ten females used chewing tobacco in 2023. Male use in the region peaked at ages 60 to 64, while female use peaked among adults aged 80 and older, a pattern consistent with long-duration, lifelong habits established decades earlier. Bangladesh, however, reverses the broader trend: chewing tobacco use was higher among females than males across all age groups older than 30, even though the products remained common among both sexes. “These findings show why chewing tobacco control cannot take a one-size-fits-all approach,” said Dr. Emmanuela Gakidou, senior author and Professor in the Department of Health Metrics Sciences at IHME. “Prevention and cessation strategies need to reflect how patterns of use differ by country, age, and sex, as well as the cultural and social factors that shape tobacco use in each setting.”

On the health outcomes side, the study employed the Burden of Proof framework, a systematic approach for quantifying the risks associated with a given exposure, to estimate the burden attributable to chewing tobacco across six outcomes: stroke, lip and oral cavity cancer, esophageal cancer, other pharyngeal cancer, laryngeal cancer, and nasopharyngeal cancer. The results challenge the common perception that chewing tobacco is primarily an oral cancer risk. Stroke accounted for the largest share of chewing tobacco-related health loss globally, at 55.9 disability-adjusted life-years, or DALYs, per 100,000 people, followed by lip and oral cavity cancer at 17.4 per 100,000. DALYs are a composite metric that combines years of life lost to premature death with years lived in disability, providing a single measure of total health loss. The prominence of stroke indicates that the cardiovascular consequences of chewing tobacco, likely driven by nicotine absorption and its effects on blood pressure and vascular function, may be as consequential as, or more consequential than, the cancers that dominate public perception of the habit.

The cancer burden remains substantial nonetheless. Chewing tobacco was responsible for 17.3 percent of lip and oral cavity cancer DALYs worldwide, a figure that rose to 30.5 percent in South Asia, where products such as betel quid with tobacco are deeply embedded in social and cultural practice. The concentration of oral cancer risk in the same region that dominates overall chewing tobacco mortality creates a compounding public health challenge: health systems in Bangladesh, India, Nepal, and neighboring countries face elevated rates of both cardiovascular disease and head and neck cancers attributable to a single exposure, straining diagnostic, surgical, and oncology services that are often already under-resourced.

The trajectory of the burden is also alarming. The number of DALYs attributed to chewing tobacco increased by 116 percent between 1990 and 2023, reaching 6.48 million globally. Most of that burden came from premature death, accounting for 6.17 million years of life lost in 2023, a signal that chewing tobacco is killing users early rather than merely adding years of chronic illness. Population growth and aging in high-prevalence countries help explain part of the increase, since even stable prevalence rates translate into more users and more deaths as populations expand, but the finding that no country achieved a significant decline in user numbers means the growth in burden has been met with essentially no counteracting progress in exposure reduction.

Why has chewing tobacco escaped the attention devoted to cigarettes? The study points to a convergence of factors: longstanding cultural and social practices that normalize the habit, widespread misconceptions that chewing products are less harmful than smoking, limited surveillance systems that fail to track smokeless tobacco use separately, and higher rates of use among rural and lower-income populations who may have less access to cessation services and health information. These dynamics have left a gap in global tobacco control, in which smokeless products are frequently absent from taxation schemes, graphic warning requirements, and cessation programs designed around cigarettes.

The authors argue that reducing chewing tobacco-related deaths and disability will require stronger integration of smokeless tobacco prevention and cessation into national tobacco control and noncommunicable disease strategies, with approaches tailored to differences by age, sex, local patterns of use, and socioeconomic context. Given that more than 90 percent of the burden clusters in ten countries for each sex, even modest, well-targeted interventions in those settings could avert a disproportionate share of the global toll. As the GBD 2023 analysis makes clear, the world’s progress against tobacco will remain incomplete until the products tucked in the cheeks of 241 million users receive the same scrutiny as the cigarette.

Subject of Research: The global, regional, and national burden of chewing tobacco use and its attributable deaths and disability from 1990 to 2023

Article Title: Chewing tobacco linked to 251,000 deaths worldwide, with more than 90% of health loss concentrated in 10 countries

Article References: Chewing tobacco linked to 251,000 deaths worldwide, with more than 90% of health loss concentrated in 10 countries. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: chewing tobacco, Global Burden of Disease, smokeless tobacco, stroke, oral cavity cancer, South Asia, DALYs, tobacco control, IHME, public health, prevalence, The Lancet Global Health

The research team, led by Lars Jacob Stovner of the Norwegian University of Science and Technology together with Ann Kristin Skrindo Knudsen, Lars Lien, Henrik Peersen, and Nils Erik Gilhus, extracted and summed GBD 2023 estimates for more than two dozen conditions, from Alzheimer’s disease and stroke to anxiety, depression, migraine, epilepsy, and addiction. Because the GBD framework has no single “brain disorders” category, the authors combined the individual diagnoses themselves, drawing on data from the Norwegian Cause of Death Registry, patient registries, and epidemiological surveys processed through GBD’s Bayesian meta-regression tool, DisMod-AT. The scale of the data effort is considerable: GBD 2023 drew on more than 100,000 data sources worldwide to generate internally consistent estimates of prevalence, incidence, and mortality for every age group, sex, and location.

The headline numbers reveal a critical asymmetry. Brain disorders were responsible for 30.77 percent of all years lived with disability (YLDs) but only 22.31 percent of all years of life lost (YLLs). In other words, these are primarily conditions people live with rather than die from, which makes them especially consequential from a socioeconomic standpoint. Mental disorders were the single largest contributor to disability, accounting for 17.56 percent of all YLDs, with anxiety disorders alone responsible for 7.35 percent. Headache disorders, dominated by migraine, contributed another 4.91 percent of all YLDs, affecting half the population in any given year. When it comes to mortality, neurological disorders dominate, chiefly because of Alzheimer’s disease and dementia, which alone accounted for 5.47 percent of all years of life lost.

The study is also the first to track how the total burden of brain disorders has shifted over time in a single country. Comparing age-standardized rates from 1990 to 2023, the researchers found a tale of two very different trajectories. On the positive side, the burden of stroke fell dramatically, with DALY rates down 65 percent over the 34-year period. This decline reflects a genuine reduction in incidence of 52 percent, alongside a 71 percent drop in mortality, driven by falling smoking rates, better control of blood pressure and cholesterol, improved diabetes management, faster acute stroke treatment, and more targeted rehabilitation. Alcohol use disorder prevalence fell 43 percent, and meningitis, once a feared killer, saw its DALY rate collapse by 89 percent thanks to vaccination and antimicrobial therapy. There were even modest, though statistically uncertain, reductions in the prevalence and burden of Alzheimer’s disease and dementia, a trend that mirrors observations elsewhere in the world and is plausibly linked to improving cerebrovascular health across generations.

Against these successes stand several deeply worrying counter-trends. The most dramatic is Parkinson’s disease, for which age-standardized prevalence rose 271 percent and incidence rose 115 percent over the study period, producing a 43 percent increase in DALY rates and an extraordinary 263 percent increase in years lived with disability. The authors note that better survival and improved diagnosis may explain part of this rise, since mortality increased far less than prevalence, but they cannot fully account for the steep increase in incidence itself. Possible contributors under investigation include environmental toxicants and even the decline of smoking in industrialized countries, a protective factor in Parkinson’s. Identifying the preventable causes of this rise, the researchers argue, should be a high scientific priority.

Mental disorders show no such improvement and, in aggregate, grew substantially. Overall mental disorder prevalence rose 29 percent, driven mainly by anxiety disorders (up 57 percent), depressive disorders (up 26 percent), and eating disorders (up 18 percent). Anxiety disorders alone saw DALY rates climb 58 percent, making them the single largest level-3 brain disorder contributor to overall disease burden in Norway at 3.79 percent of all DALYs. None of the major mental disorders showed improvement over three decades, and the authors point to shifting diagnostic practices, increased awareness, and the documented rise in mental health problems among young girls as likely contributing factors. Similar trends have been reported in the United Kingdom, suggesting the pattern is not unique to Norway. Compounding the concern, drug use disorders went in the opposite direction to alcohol, with prevalence up 23 percent and mortality from drug use soaring 97 percent, a trend the authors link partly to the increasing availability of potent synthetic opioids and poly-substance abuse.

The methodology behind these estimates deserves attention, both for its power and its limitations. GBD quantifies health loss by multiplying disease prevalence by disability weights derived from community surveys of tens of thousands of people across many countries, scaled from zero to one. Years of life lost are calculated against the highest observed life expectancy globally, ensuring that no population is penalized for biology alone. Crucially, the GBD framework corrects for comorbidity in a multiplicative rather than additive fashion, so summing individual conditions to estimate the total brain disorder burden does not inflate the result. Yet the authors are candid that many Norwegian figures rest on extrapolations from neighboring and epidemiologically similar countries, and that residual bias from changing diagnostic definitions cannot be excluded. Some categories, notably autism spectrum disorder and central nervous system cancers, carry uncertainty intervals so wide that no firm trend conclusions can be drawn, and neurotrauma had to be excluded from the total burden entirely because GBD reports injuries by cause rather than anatomical site, meaning the reported figures are minimum estimates.

The socioeconomic implications extend well beyond healthcare budgets. Many of the most common brain disorders, including ADHD, migraine, epilepsy, multiple sclerosis, schizophrenia, and depression, strike in childhood, adolescence, or early adulthood, precisely the years when people build careers, relationships, and families. Early-onset conditions reduce workforce participation, generating costs through disability pensions, absenteeism, and reduced productivity at work, while their cumulative effects ripple through later life outcomes including marriage, careers, and child-rearing. Conditions that appear later in life, such as dementia, Parkinson’s disease, and stroke, impose a different but equally heavy load: intensive caregiving demands on relatives and mounting pressure on nursing home capacity. With Norway’s population continuing to age, the total number of stroke and dementia patients will likely remain high even as age-specific rates decline.

The message for policymakers is clear and double-edged. Where prevention and treatment have been effective, the data show measurable, decades-long improvements, as stroke and meningitis demonstrate. But for anxiety, depression, and headache disorders, three of the most burdensome conditions in the entire analysis, thirty years have delivered essentially no progress, and for Parkinson’s disease and drug use disorders the situation is actively deteriorating. The GBD study identifies few modifiable risk factors for mental disorders, underscoring how much basic research remains to be done. The authors urge continued monitoring of brain health through future GBD iterations, arguing that only systematic measurement can evaluate the real-world impact of new and often very costly treatments, pinpoint emerging threats before they become crises, and direct scarce research and healthcare resources to where they will save the most healthy years of life. As Norway’s experience shows, the brain is both the greatest single source of health loss in a modern welfare state and, until now, one of its most fragmented and neglected policy priorities.

Subject of Research: The national burden of neurological, mental, and substance use disorders in Norway and their trends from 1990 to 2023 using Global Burden of Disease Study 2023 data.

Article Title: The burden of brain disorders in Norway: an analysis of data from the global burden of disease study 2023

Article References: Stovner, L. J., Skrindo Knudsen, A. K., Lien, L., Peersen, H., & Gilhus, N. E. (2026). The burden of brain disorders in Norway: an analysis of data from the global burden of disease study 2023. The Lancet Regional Health – Europe, 70, Article 101857. https://doi.org/10.1016/j.lanepe.2026.101857

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101857

Keywords: brain disorders, disease burden, DALYs, Norway, Global Burden of Disease, mental health, neurological disorders, Parkinson's disease, stroke, anxiety disorders, substance use, disability